Primary head and neck squamous cell carcinoma (HNSCC): laryngeal, hypopharyngeal, oropharyngeal cancer research hub

Accelerating the development and implementation of DNA damage inhibitor and radiotherapy treatment (with or without immunotherapy) in head and neck squamous cell carcinoma

This UK clinical trial is testing a new drug called ceralasertib alongside standard radiotherapy for head and neck cancer. Doctors want to find out the safest and most effective dose of the drug to help stop cancer cells repairing themselves, without causing unmanageable side effects for patients.